Max Nisen, Columnist

Trump's New Drug-Pricing Move Won't Cut Prices

A proposed change to a discount program will help pharma, hurt hospitals.

July 14, 2017 at 4:10 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

1500048615_GettyImages-516540106 — Photographer: Ralph Freso

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

We've come a long way from President Donald Trump telling the pharmaceutical industry it was getting away with murder.

His administration's Center for Medicaid and Medicaid Services (CMS) on Thursday proposed deep cuts to reimbursement rates for the 340B drug-discount program, which mandates big price cuts for "safety-net" hospitals that treat a lot of poor patients.